iShares Biotechnology ETF
889 hedge funds and large institutions have $5.28B invested in iShares Biotechnology ETF in 2024 Q2 according to their latest regulatory filings, with 78 funds opening new positions, 201 increasing their positions, 330 reducing their positions, and 64 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
1% less capital invested
Capital invested by funds: $5.32B → $5.28B (-$35.8M)
39% less repeat investments, than reductions
Existing positions increased: 201 | Existing positions reduced: 330
76% less call options, than puts
Call options by funds: $301M | Put options by funds: $1.27B
Holders
889
Holding in Top 10
11
Calls
$301M
Puts
$1.27B
Top Buyers
| 1 | +$121M | |
| 2 | +$68.9M | |
| 3 | +$54.8M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$29.9M |
| 5 |
Two Sigma Investments
New York
|
+$15.9M |
Top Sellers
| 1 | -$91.5M | |
| 2 | -$72.8M | |
| 3 | -$39.7M | |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$29.4M |
| 5 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
-$26.7M |